Cargando...
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a biologically based personalization of anticancer treatments. In particular, the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells provided a specific target in these H...
Gardado en:
| Publicado en: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513878/ https://ncbi.nlm.nih.gov/pubmed/28744140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S122397 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|